Addition of Atezolizumab Improves PFS in NSCLC With Liver Mets
June 4th 2019According to a subgroup analysis from the phase III IMpower150 trial presented at the 2019 ASCO Annual Meeting, the addition of immunotherapy to bevacizumab and a chemotherapy doublet improved progression-free survival in patients with non–small cell lung cancer and baseline liver metastases.
Read More
FDA Unveils Project Facilitate to Ease Expanded Access to Experimental Cancer Treatments
June 4th 2019Announced at the 2019 ASCO Annual Meeting, the FDA is rolling out a pilot program that will provide more information and assistance for acquiring expanded access (EA) to investigational therapies for both oncologists and patients. The program is being called Project Facilitate.
Read More
Findings From Two Studies Show Positive Results From Neoadjuvant Immunotherapy in NSCLC
June 3rd 2019Findings from 2 studies of patients with operable early-stage non–small cell lung cancer showed preoperative immunotherapy had positive activity and favorable toxicity, according to a presentation at the 2019 ASCO Annual Meeting, and phase III clinical trials are already testing these stratgies.
Read More
Sexual Harassment in Training, Practice Reported by Two-Thirds of Gynecologic Oncologists
June 3rd 2019Results from a survey conducted by the Society of Gynecologic Oncology found that 70% of female and more than half of male gynecologic oncologists in the United States were victims of sexual harassment in either training or practice; and of those, only 10% said they reported their experiences.
Read More
Eligibility for Clinical Trial Participation in NSCLC Could Double
June 3rd 2019Nearly double the number of patients with advanced non-small cell lung cancer would be eligibile for clinical trial enrollment if a broader set of eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research was implemented, according to data presented at the 2019 ASCO Annual Meeting.
Read More
Laparoscopic Surgery Demonstrates Similar Survival Rates to Open Surgery for CRC Liver Metastases
June 3rd 2019Patients with colorectal cancer and liver metastases who underwent laparoscopic surgery had similar long-term rates of overall survival compared with patients who had open liver surgery, according to results of the randomized OSLO-COMET trial. These findings were presented in a press briefing during the 2019 ASCO Annual Meeting.
Read More
Enfortumab Vedotin Achieves Responses in Advanced Urothelial Carcinoma
June 3rd 2019According to data from the phase II EV-201 study presented at the 2019 ASCO Annual Meeting, 44% of patients with locally advanced or metastatic urothelial cancer achieved responses with enfortumab vedotin. This includes 12% of patients reached a complete response to treatment. Median overall survival time for patients was 11.7 months.
Read More
Final KEYNOTE-048 Results With Frontline Pembrolizumab in Recurrent/Metastatic HNSCC
June 3rd 2019Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Read More
Risk of Progression Reduced With Isatuximab Triplet in Phase III Multiple Myeloma Trial
June 3rd 2019Progression-free survival was significantly improved with the triplet combination of isatuximab, pomalidomide, and low-dose dexamethasone compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III ICARIA-MM trial presented at the 2019 ASCO Annual Meeting.<br />
Read More
Subcutaneous Daratumumab Found Noninferior to IV Formulation in Multiple Myeloma
June 3rd 2019A subcutaneous formulation of daratumumab showed similar efficacy to the original intravenous formulation of daratumumab in the phase III COLUMBA trial of patients with relapsed/refractory multiple myeloma. The subcutaenous flat-dose of daratumumab also showed a reduction in the treatment burden, according to results presented at the 2019 ASCO Annual Meeting.
Read More
Patients With Locally Advanced CSCC See Promising Efficacy with Cemiplimab
June 2nd 2019Cemiplimab demonstrated substantial antitumor activity and induced durable responses in patients with locally advanced cutaneous squamous cell carcinoma who were enrolled in the pivotal EMPOWER-CSCC-1 phase II study, and these results were similar to previously reported data in patients with metastatic CSCC enrolled in the same study.
Read More
Racial Disparities in Cancer Care Access Reduced With Medicaid Expansion
June 2nd 2019Racial disparities in time to cancer treatment are nearly eliminated since the expansion of Medicaid, according to the results from a study presented at the 2019 ASCO Annual Meeting. Analysis on the impact of the Affordable Care Act Medicaid expansion showed Medicaid was associated with a 6.1 percentage point improvement in timely access to cancer care treatment for African American patients versus 2.1 in white patients.
Read More
Ovarian Cancer Diagnosis, Time to Treatment Improved Since ACA
June 2nd 2019After passage of the Affordable Care Act, women with ovarian cancer who were pre-medicare-aged were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis compared to prior to the ACA, according to findings presented at the 2019 ASCO Annual Meeting.
Read More
Lurbinectedin Monotherapy Demonstrates Promising Responses in Second-Line SCLC
June 2nd 2019Single-agent lurbinectedin induced an overall response rate of 35.2% in the second-line setting for the treatment of patients with small cell lung cancer in a phase II basket trial, presented at the 2019 ASCO Annual Meeting.
Read More
Open-Source System Introduced to Guide, Improve Cancer Treatment Through EHR Systems
June 2nd 2019Details on a prototype system were released during the 2019 ASCO Annual Meeting by a consortium of cancer care institutions that was designed to use electronic health record systems to provide real-world patient data that could guide research and improve cancer treatment.
Read More
Socioeconomic Disparities Influence Survival in Multiple Myeloma
June 2nd 2019According to a study authors performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes, higher incomes and having private insurance were associated with a significantly greater probability of survival for patients with multiple myeloma.
Read More
Survival Improved at 3 Years With Enzalutamide Versus Other Anti-Androgens in mHSPC
June 2nd 2019Survival was increased with the treatment of enzalutamide plus standard of care compared with the use of other non-steroidal anti-androgens plus SOC for patients with metastatic hormone-sensitive prostate cancer. Results from an interim analysis of the phase III ENZAMET trial presented at the 2019 ASCO Annual Meeting showed that 80% of men with mHSPC were alive after 3 years with enzalutamide treatment compared with 72%.
Read More
PFS Increased With Olaparib as Maintenance Therapy for BRCA+ Metastatic Pancreatic Cancer
June 2nd 2019The PARP inhibitor olaparib significantly improved progression-free survival in patients with germline BRCA-mutated metastatic pancreatic cancer compared to placebo when used as maintenance therapy in the phase III POLO trial, presented at the 2019 ASCO Annual Meeting.
Read More
Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC
June 2nd 2019Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer.
Read More
Patients With Stage III Melanoma Have Sustained Efficacy With Adjuvant Ipilimumab at 7 Years
June 2nd 2019Updated data from the phase III EORTC 18071 study showed that patients with surgically resected high-risk, stage III melanoma experienced a 25% reduction in the risk of recurrence or death with adjuvant ipilimumab compared with placebo.
Read More
Survival Is Improved in Metastatic Castration-Sensitive Prostate Cancer With Apalutamide
June 1st 2019Patients with metastatic castration-resistant prostate cancer who received apalutamide plus androgen deprivation therapy had a 33% reduced risk of death compared with patients taking androgen deprivation therapy alone in the phase III TITAN trial. Topline results from the trial were presented at the 2019 ASCO Annual Meeting and simultaneously published in the <em>New England Journal of Medicine.</em>
Read More
Updated Results from KEYNOTE-001 Show Favorable 5-Year OS Rates in Advanced NSCLC
June 1st 2019Overall survival from the KEYNOTE-001 trial in patients with advanced non–small cell lung cancer showed treatment with pembrolizumab monotherapy produced more favorable rates of response at 5 years when compared with historical, pre-immunotherapy standard-of-care regimens.
Read More
Improved OS Observed in HR+, HER2- Advanced Breast Cancer With Ribociclib Plus ET
June 1st 2019According to findings from the phase III MONALEESA-7 trial, peri and premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared with 46% for placebo and endocrine therapy.
Read More
Less AEs, Similar Efficacy Reported in Advanced G/GEJ Cancers With Frontline Pembrolizumab
June 1st 2019Patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer had non-inferior overall survival with frontline pembrolizumab compared with standard chemotherapy, according to results from the phase III KEYNOTE-062 trial.
Read More
Highlighting Key Trials in Kidney Cancer
June 1st 2019Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.
Read More
ASCO to Recognize Leaders Transforming Cancer Care Around the World
May 31st 2019Ahead of the 2019 ASCO Annual Meeting, the American Society of Clinical Oncology announced leaders in the field of oncology who will be recognized during the upcoming annual meeting. The winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards will be acknowledged for their work toward transforming cancer care around the world.
Read More
Oncology Experts Select Top Abstracts Ahead of 2019 ASCO Annual Meeting
May 29th 2019In an interview with <em>Targeted Oncology</em>, experts in gynecology, gastrointestinal, genitourinary, lung, and breast cancers spoke to the significance of the abstracts they are most looking forward to at the 2019 ASCO Annual Meeting.
Read More
Promising Responses Seen With Entrectinib in Pediatric Cancers, Including CNS Tumors
May 16th 2019One-hundred percent of pediatric patients with CNS and solid tumors harboring <em>NTRK1/2/3</em>, <em>ROS1</em>, or <em>ALK</em> gene fusions or mutations achieved objective responses with entrectinib, according to the phase I/Ib STARTRK-NG trial data presented in a press cast ahead of the 2019 ASCO Annual Meeting.
Read More
Discussion on Trial Investigating Erdafitinib in Patients With Urothelial Cancer
June 8th 2018Arlene O. Siefker-Radtke, MD, professor of genitourinary medical oncology at MD Anderson Cancer Center, discusses the results presented at the 2018 ASCO Annual Meeting from a phase II cohort investigating erdafitinib in previously treated patients with urothelial cancer. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that targets FGFR 1 through 4 and has previously shown promising activity.
Read More
Activity in Relapsed Progressive TNBC With Niraparib Plus Pembrolizumab
June 6th 2018According to a preliminary prospective study presented at the 2018 ASCO Annual Meeting, half of patients with metastatic triple-negative breast cancer achieved disease control with a treatment combination of a poly polymerase inhibitor and an anti–PD-1 agent.
Read More